You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt to help with their weight loss efforts. Ozempic is actually for type-2 ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...

The foundation behind Novo Nordisk, which makes weight-loss drugs Ozempic and Wegovy, will invest €80 million ($93 million) ...

Over 60 novel drug candidates are in late-stage clinical trials in China, and these will potentially compete directly with US ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

A little over a year after celebrating its 30th anniversary in China with a major production upgrade, Novo Nordisk is back ...

Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next year, its CEO said on Tuesday, the latest Chinese company to join the race ...

HONG KONG] The biotechnology industry is experiencing a tectonic shift, driven by Chinese drugmakers who have come a long way ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

There's nothing preventing patients from lying when asked about eating disorders as part of the telehealth screening and ...